AMSTERDAM, Oct. 12, 2015 /PRNewswire/ -- Royal Philips
(NYSE: PHG, AEX: PHIA), a leader in the digitization of pathology,
today announced a collaboration with Genomic Health, Inc. (NASDAQ:
GHDX), a world leading provider of genomic-based diagnostic tests,
to leverage Philips digital pathology tools in Genomic Health's
continuing scale up of its molecular diagnostic testing processes.
Pathology involves the examination of patient tissue samples and
plays a crucial role in the diagnosis and treatment of a wide
variety of diseases, including cancer. Philips is a pioneer and
leader in the digitization of pathology. Pathologic
evaluation of tumor tissue specimens is a critical step in the
genomic testing process conducted by Genomic Health's Clinical
Reference Laboratory. These genomic tests support physicians'
ability to deliver personalized treatment for patients diagnosed
with complex disease such as cancer.
"Digitization has the potential to open new opportunities for
increased efficiency and a reduction in the shortcomings of a
traditional analog histopathology workflow," said Russell Granzow, General Manager of Philips
Digital Pathology Solutions. "Philips is driving the evolution
towards unified patient data to ensure pathologists are empowered
to meet the increasing demand in cancer care for more precise
diagnostics."
"By utilizing Philips's latest digital pathology solution, we
are providing our pathologists with a state-of-the-art system that
will provide the next level of scalability and efficiency for our
overall pre-analytical process, adding new capabilities that will
be increasingly important as worldwide demand for Genomic Health's
tests continues to grow," said Jon
Cassel, Senior Vice President of Operations at Genomic
Health.
Philips lntelliSite Pathology Solution* is an automated digital
pathology image creation, management and analysis system comprised
of an ultra-fast pathology slide scanner, an image management
system and case viewer. This solution is complemented by advanced
software tools to manage the scanning, storage, presentation,
research analysis and sharing of information.
* In the European Union, the Philips IntelliSite Pathology
Solution is CE Marked under the European Union's 'In Vitro
Diagnostics Directive' for in vitro diagnostic use.In Canada, the Philips IntelliSite Pathology
Solution is licensed by Health Canada for in vitro diagnostic
use. In the United States, the
Philips IntelliSite Pathology Solution can be used for in vitro
diagnostic use for Manual Read of
the Digital HER2 Application and is available for research use
only. The Philips IntelliSite Pathology Solution is registered for
in vitro diagnostic use in Singapore and Middle
East.
For further information, please contact:
Hans Driessen
Philips Digital Pathology Solutions
Tel.: +31 6 10 610 417
E-mail: hans.driessen@philips.com
Steve
Klink
Philips Group Communications
Tel.: +31 6 1088 8824
E-mail: steve.klink@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX:
PHIA) is a diversified health and well-being company, focused on
improving people's lives through meaningful innovation in the areas
of Healthcare, Consumer Lifestyle and Lighting. Headquartered in
the Netherlands, Philips posted
2014 sales of EUR 21.4 billion and
employs approximately 106,000 employees with sales and services in
more than 100 countries. The company is a leader in cardiac care,
acute care and home healthcare, energy efficient lighting solutions
and new lighting applications, as well as male shaving and grooming
and oral healthcare. News from Philips is located at
www.philips.com/newscenter.
Logo -
http://photos.prnewswire.com/prnh/20140122/NE50581LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/philips-teams-up-with-genomic-health-to-utilize-innovative-digital-pathology-solutions-to-optimize-pre-analytical-specimen-processing-300157655.html
SOURCE Royal Philips